VTRS - Viatris - Stock Price & Dividends

Viatris Inc. is a global healthcare company that operates through four main segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company's diverse portfolio includes prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).

These products cater to various therapeutic areas, such as noncommunicable and infectious diseases. The company's biosimilars focus on oncology, immunology, endocrinology, ophthalmology, and dermatology, while its APIs support the production of medications for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas.

In addition to its products, Viatris Inc. offers support services to help patients better manage their health. These services include diagnostic clinics, educational seminars, and digital tools. The company distributes its products in various forms, such as oral solid doses, injectables, complex dosage forms, and APIs, to a range of customers, including retail and pharmacy establishments, wholesalers and distributors, payers, insurers, governments, and institutions.

The company's distribution network is extensive, with products sold through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. Viatris Inc.'s product portfolio includes well-known brands such as Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri, among others.

The company has established collaboration and licensing agreements with other pharmaceutical companies, such as Revance Therapeutics, Inc. and Momenta Pharmaceuticals, Inc. With a rich history dating back to 1961, Viatris Inc. is headquartered in Canonsburg, Pennsylvania, and continues to play a significant role in the global healthcare industry.